Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)

被引：1

作者：

Highland, Kristin B. ^{[1
]}

Kuwana, Masataka ^{[2
]}

Azuma, Arata ^{[3
]}

Fischer, Aryeh ^{[4
]}

Maher, Toby M. ^{[5
,6
]}

Mayes, Maureen D. ^{[7
]}

Raghu, Ganesh ^{[8
]}

Girard, Mannaig ^{[9
]}

Kohlbrenner, Veronika ^{[10
]}

Clerisme-Beaty, Emmanuelle ^{[11
]}

Alves, Margarida ^{[11
]}

Distler, Oliver ^{[12
]}

机构：

[1] Cleveland Clin, Resp Inst, Cleveland, OH 44106 USA

[2] Nippon Med Sch, Dept Allergy & Rheumatol, Grad Sch Med, Tokyo, Japan

[3] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Tokyo, Japan

[4] Univ Colorado, Sch Med, Denver, CO USA

[5] Imperial Coll London, Natl Heart & Lung Inst, London, England

[6] Royal Brompton Hosp, Res Clin Res Facil, Natl Inst Hlth, London, England

[7] Univ Texas Houston, McGovern Med Sch, Div Rheumatol & Clin Immunogenet, Houston, TX USA

[8] Univ Washington, Seattle, WA 98195 USA

[9] Boehringer Ingelheim France SAS, Reims, France

[10] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA

[11] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[12] Univ Hosp Zurich, Dept Rheumatol, Zurich, Switzerland

来源：

EUROPEAN RESPIRATORY JOURNAL | 2019年 / 54卷

关键词：

D O I：

10.1183/13993003.congress-2019.PA4731

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

PA4731

引用

页数：2

共 50 条

[31] CONTINUED TREATMENT WITH NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD): THREEYEAR DATA FROM SENSCIS-ON
Allanore, Y.
Vonk, M.
Distler, O.
Azuma, A.
Mayes, M.
James, A.
Kohlbrenner, V.
Alves, M.
Khanna, D.
Highland, K.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 281 - 281
[32] Changes in Imaging Markers in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib: Sub-Study of the SENSCIS Trial
Bonella, F.
Humphries, S.
Hachulla, E.
Hamblin, M.
Ogura, T.
Wormanns, D.
Ittrich, C.
Risse, F.
Alves, M.
Gahlemann, M.
Lynch, D. A.
PNEUMOLOGIE, 2021, 75 : S24 - S25
[33] Changes in Imaging Markers in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib: Sub-Study of the SENSCIS Trial
Humphries, Stephen
Hachulla, Eric
Hamblin, Mark
Ogura, Takashi
Wormanns, Dag
Ittrich, Carina
Risse, Frank
Alves, Margarida
Gahlemann, Martina
Lynch, David
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[34] Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Beyond 52 Weeks: Data from the SENSCIS Trial
Maher, T. M.
Distler, O.
Allanore, Y.
Ogura, T.
Varga, J.
Vettori, S.
Crestani, B.
von Wangenheim, U.
Quaresma, M.
Alves, M.
Stowasser, S.
Assassi, S.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[35] BASELINE CHARACTERISTICS OF PATIENTS WITH IMPROVEMENT OR PROGRESSION OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) DURING THE SENSCIS TRIAL
Hoffmann-Vold, A. M.
Hachulla, E.
Herrick, A.
Moua, T.
Riemekasten, G.
Vonk, M.
James, A.
Alves, M.
Distler, O.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 720 - 720
[36] Nailfold Capillaroscopy in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib
Smith, Vanessa
Denton, Christopher
Herrick, Ariane
Ittrich, Carina
Alves, Margarida
Cutolo, Maurizio
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1241 - 1243
[37] IS THE RATE OF LUNG FUNCTION DECLINE THE SAME IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED ILD (SSC-ILD) WHO EXPERIENCE WEIGHT LOSS? DATA FROM THE SENSCIS TRIAL
Lescoat, A.
Jouneau, S.
Crestani, B.
Riemekasten, G.
Kondoh, Y.
Smith, V.
Patel, N.
Huggins, J.
Stock, C.
Gahlemann, M.
Alves, M.
Denton, C.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1106 - 1106
[38] Effect of nintedanib on circulating biomarkers in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD)*
Prasse, Autoren A.
Assassi, S.
Kuwana, M.
Denton, C.
Maher, T.
Diefenbach, C.
Ittrich, C.
Gahlemann, M.
Distler, O.
PNEUMOLOGIE, 2023, 77 : S53 - S54
[39] EFFECTS OF NINTEDANIB ON CIRCULATING BIOMARKERS IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
Assassi, S.
Kuwana, M.
Denton, C. P.
Maher, T.
Diefenbach, C.
Ittrich, C.
Gahlemann, M.
Distler, O.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 719 - 720
[40] Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Three-Year Data from SENSCIS-ON
Allanore, Yannick
Vonk, Madelon
Distler, Oliver
Azuma, Arata
Mayes, Maureen
James, Alexandra
Kohlbrenner, Veronika
Alves, Margarida
Khanna, Dinesh
Highland, Kristin
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3032 - 3033

← 1 2 3 4 5 →